Literature DB >> 25523969

Emergence of clonally related multidrug resistant Haemophilus influenzae with penicillin-binding protein 3-mediated resistance to extended-spectrum cephalosporins, Norway, 2006 to 2013.

D Skaare1, I L Anthonisen, G Kahlmeter, E Matuschek, O B Natås, M Steinbakk, A Sundsfjord, B E Kristiansen.   

Abstract

Resistance to cephalosporins in Haemophilus influenzae is usually caused by characteristic alterations in penicillin-binding protein 3 (PBP3), encoded by the ftsI gene. Resistance to extended-spectrum cephalosporins is associated with high-level PBP3-mediated resistance (high-rPBP3), defined by the second stage S385T substitution in addition to a first stage substitution (R517H or N526K). The third stage L389F substitution is present in some high-rPBP3 strains. High-rPBP3 H. influenzae are considered rare outside Japan and Korea. In this study, 30 high-rPBP3 isolates from Norway, collected between 2006 and 2013, were examined by serotyping, multilocus sequence typing (MLST), ftsI sequencing, detection of beta-lactamase genes and minimum inhibitory concentration (MIC) determination. MICs were interpreted according to clinical breakpoints from the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Respiratory isolates predominated (proportion: 24/30). The 30 isolates included one serotype f isolate, while the remaining 29 lacked polysaccharide capsule genes. Resistance to extended-spectrum cephalosporins (cefixime, 29 isolates/30 isolates; cefepime, 28/30; cefotaxime, 26 /30; ceftaroline, 26/30; ceftriaxone, 14/30), beta-lactamase production (11/30) and co-resistance to non-beta-lactams (trimethoprim-sulfamethoxazole, 13/30; tetracycline, 4/30; chloramphenicol, 4/30; ciprofloxacin, 3/30) was frequent. The N526K substitution in PBP3 was present in 23 of 30 isolates; these included a blood isolate which represents the first invasive S385T + N526K isolate reported from Europe. The L389F substitution, present in 16 of 30 isolates, coincided with higher beta-lactam MICs. Non-susceptibility to meropenem was frequent in S385T + L389F + N526K isolates (8/12). All 11 beta-lactamase positive isolates were TEM-1. Five clonal groups of two to 10 isolates with identical MLST-ftsI allelic profiles were observed, including the first reported high-rPBP3 clone with TEM-1 beta-lactamase and co-resistance to ciprofloxacin, tetracycline, chloramphenicol and trimethoprim-sulfamethoxazole. Prior to this study, no multidrug resistant high-rPBP3 H. influenzae had been reported in Norway. Intensified surveillance of antimicrobial resistance is needed to guide empiric therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25523969     DOI: 10.2807/1560-7917.es2014.19.49.20986

Source DB:  PubMed          Journal:  Euro Surveill        ISSN: 1025-496X


  19 in total

1.  Ampicillin-resistant Haemophilus influenzae isolates in Geneva: serotype, antimicrobial susceptibility, and β-lactam resistance mechanisms.

Authors:  A Cherkaoui; S M Diene; S Emonet; G Renzi; P Francois; J Schrenzel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-07-18       Impact factor: 3.267

2.  Antibiotic susceptibility and molecular analysis of invasive Haemophilus influenzae in Canada, 2007 to 2014.

Authors:  Raymond S W Tsang; Michelle Shuel; Kathleen Whyte; Linda Hoang; Gregory Tyrrell; Greg Horsman; John Wylie; Frances Jamieson; Brigitte Lefebvre; David Haldane; Rita R Gad; Gregory J German; Robert Needle
Journal:  J Antimicrob Chemother       Date:  2017-05-01       Impact factor: 5.790

3.  Haemophilus influenzae with Non-Beta-Lactamase-Mediated Beta-Lactam Resistance: Easy To Find but Hard To Categorize.

Authors:  Dagfinn Skaare; Astrid Lia; Anja Hannisdal; Yngvar Tveten; Erika Matuschek; Gunnar Kahlmeter; Bjørn-Erik Kristiansen
Journal:  J Clin Microbiol       Date:  2015-09-09       Impact factor: 5.948

4.  Carbapenem-Nonsusceptible Haemophilus influenzae with Penicillin-Binding Protein 3 Containing an Amino Acid Insertion.

Authors:  Kazuki Kitaoka; Kouji Kimura; Hiromitsu Kitanaka; Hirotsugu Banno; Wanchun Jin; Jun-Ichi Wachino; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

5.  Antimicrobial resistance among Haemophilus influenzae isolates responsible for lower respiratory tract infections in Poland, 2005-2019.

Authors:  Marlena Kiedrowska; Weronika Jasmina Foryś; Agnieszka Gołębiewska; Izabela Waśko; Patrycja Ronkiewicz; Alicja Kuch; Izabela Wróbel-Pawelczyk; Michał Wroczyński; Waleria Hryniewicz; Anna Skoczyńska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2022-05-18       Impact factor: 3.267

6.  Haemophilus influenzae one day in Denmark: prevalence, circulating clones, and dismal resistance to aminopenicillins.

Authors:  Niels Nørskov-Lauritsen; Nanna Pedersen; Janni U H Lam; Hans L Nielsen; Carl M Kobel; Dennis S Hansen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2021-04-23       Impact factor: 3.267

7.  The Epidemiology of Invasive Haemophilus influenzae Non-Serotype B Disease in Ontario, Canada from 2004 to 2013.

Authors:  Shalini Desai; Frances B Jamieson; Samir N Patel; Chi Yon Seo; Vica Dang; Jill Fediurek; Debeka Navaranjan; Shelley L Deeks
Journal:  PLoS One       Date:  2015-11-16       Impact factor: 3.240

Review 8.  Potential targets for next generation antimicrobial glycoconjugate vaccines.

Authors:  Francesca Micoli; Paolo Costantino; Roberto Adamo
Journal:  FEMS Microbiol Rev       Date:  2018-05-01       Impact factor: 16.408

9.  Polymorphism of ftsI gene in Haemophilus influenzae and emergence of cefotaxime resistance in two Tunisian hospitals.

Authors:  S Ferjani; I Sassi; M Saidani; E Mhiri; A Ghariani; I Boutiba Ben Boubaker; L Slim; S Amine
Journal:  New Microbes New Infect       Date:  2020-05-05

Review 10.  The Interplay Between Immune Response and Bacterial Infection in COPD: Focus Upon Non-typeable Haemophilus influenzae.

Authors:  Yu-Ching Su; Farshid Jalalvand; John Thegerström; Kristian Riesbeck
Journal:  Front Immunol       Date:  2018-11-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.